First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial
First-line Serplulimab plus Chemotherapie beim extensivierten kleinzelligen Lungenkarzinom: aktualisierte Ergebnisse und Biomarkeranalyse der randomisierten ASTRUM-005-Studie
Cancer Communications · 2025-08 · 45 (8) · 990-1009
DOI: 10.1002/cac2.70032 ↗Auf einen Blick
Serplulimab plus Chemotherapie verlängerte das Gesamtüberleben bei zuvor unbehandeltem ES-SCLC gegenüber Chemotherapie allein. Explorative Analysen zeigten mögliche Biomarker für das Ansprechen.
Fragestellung
Verbessert Serplulimab plus Chemotherapie im Vergleich zu Chemotherapie allein das Überleben bei zuvor unbehandeltem ES-SCLC, und welche Biomarker sind damit assoziiert?
Methode
Randomisierte klinische Studie; 585 Patient:innen in 2:1-Randomisierung; Serplulimab oder Placebo alle 3 Wochen plus Carboplatin und Etoposid; medianes Follow-up 19,8 Monate.
Ergebnisse
ITT: medianes OS 15,8 Monate mit Serplulimab vs. 11,1 Monate mit Placebo; HR 0,62 (95 %-KI 0,50–0,76; P < 0,001). 181 DEPs, daraus 15-Protein-Signatur. RB1- oder Notch-Mutationen waren mit besseren Endpunkten assoziiert.
Schlussfolgerung der Autor:innen
Serplulimab in der Erstlinie brachte bei ES-SCLC einen anhaltenden klinischen Nutzen gegenüber Placebo. Eine 15-Protein-Signatur sowie RB1- oder Notch-Genmutationen könnten prädiktive Biomarker sein.
Kernaussagen
- OS: 15,8 vs. 11,1 Monate
- HR 0,62 (95 %-KI 0,50–0,76)
- Mögliche Biomarker: 15-Protein-Signatur, RB1- und Notch-Mutationen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Communications, online erschienen am 29.05.2025. Verfasst von Ying Cheng und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Jilin Cancer Hospital, Changchun, Jilin, P. R. China. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Henlius Biotech Inc., National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The ASTRUM‐005 study previously demonstrated a significant overall survival (OS) benefit with serplulimab (a programmed death 1 inhibitor) plus chemotherapy versus chemotherapy alone in previously untreated extensive‐stage small‐cell lung cancer (ES‐SCLC). Here, we report updated efficacy and safety results after an extended median follow‐up of 19.8 months, along with the first report on findings from exploratory biomarker analyses.
Methods
A total of 585 patients were randomized in a 2:1 ratio to receive 4.5 mg/kg serplulimab ( n = 389) or placebo ( n = 196) intravenously every 3 weeks, together with carboplatin and etoposide. The primary endpoint was OS. In addition, genomic profiling was performed to identify mutated genes, and quantitative serum proteome profiling was conducted to identify differentially expressed proteins (DEPs) between responders and non‐responders of serplulimab plus chemotherapy. Regression analysis was subsequently used to construct a protein signature based on the DEPs. The associations between efficacy outcomes (objective response rate [ORR], OS, and progression‐free survival [PFS]) and gene mutation status or DEP expression were also examined with regression analysis. Furthermore, the prognostic value of hematological parameters was evaluated.
Results
In the intent‐to‐treat population, the median OS was 15.8 months in the serplulimab group versus 11.1 months in the placebo group (hazard ratio, 0.62; 95% confidence interval, 0.50‐0.76; P < 0.001). We identified 181 DEPs between responders and non‐responders in the serplulimab group, from which a 15‐protein signature was constructed. In the serplulimab group, patients with a higher 15‐protein signature score were associated with significantly longer OS and PFS. Also, patients harboring tumor‐suppressor retinoblastoma‐1 ( RB1 ) mutations or mutations in Notch pathway members showed improved ORR, OS, or PFS compared with their wild‐type counterparts. Baseline neutrophil‐to‐lymphocyte ratio (NLR) and lactate dehydrogenase (LDH) level were independent prognosticators of patients with ES‐SCLC.
Conclusions
First‐line serplulimab provided a sustained clinical benefit over placebo in patients with ES‐SCLC. A 15‐protein signature and mutations in RB1 or Notch pathway genes may serve as predictive biomarkers for benefits from serplulimab plus chemotherapy, while baseline NLR and LDH were independent prognosticators for ES‐SCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Jilin Cancer Hospital, Changchun, Jilin, P. R. China.
- Department of Oncology, Xuzhou Central Hospital, Xuzhou, Jiangsu, P. R. China.
- Department of Thoracic Medical Oncology, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, P. R. China.
- Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, P. R. China.
- Department of Oncology, Jiamusi Cancer Hospital, Jiamusi, Heilongjiang, P. R. China.
- Department of Respiratory Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, P. R. China.
ORCID-Profile: Ying Cheng, Lin Wu
Förderung
- Shanghai Henlius Biotech Inc.
- National Natural Science Foundation of China
Zitieren
APA
Cheng, Y., Zhang, S., Han, L., Wu, L., Chen, J., Zhao, P., Sun, H., Wen, G., Ji, Y., Zimina, A., Shi, J., Pan, Z., Shi, J., Wang, X., Bai, Y., Melkadze, T., Pan, Y., Min, X., Viguro, M., …, & ASTRUM‐005 Study Group (2025). First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial. Cancer Communications, 45(8), 990-1009. https://doi.org/10.1002/cac2.70032
Vancouver
Cheng Y, Zhang S, Han L, Wu L, Chen J, Zhao P, et al. First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial. Cancer Communications. 2025;45(8):990-1009. doi:10.1002/cac2.70032
BibTeX
@article{Cheng2025,
author = {Cheng, Ying and Zhang, Shuang and Han, Liang and Wu, Lin and Chen, Jun and Zhao, Peiyan and Sun, Hongmei and Wen, Guilan and Ji, Yinghua and Zimina, Anastasia and Shi, Jianhua and Pan, Zhijie and Shi, Jinsheng and Wang, Xicheng and Bai, Yuansong and Melkadze, Tamar and Pan, Yueyin and Min, Xuhong and Viguro, Maksym and Li, Xingya and Zhao, Yanqiu and Yang, Junquan and Makharadze, Tamta and Arkania, Ekaterine and Yu, Haoyu and Li, Jing and Yang, Fang and Yang, Xinyi and Ling, Chen and Wang, Qingyu and Shan, Yongqiang and Zhu, Jun and ASTRUM‐005 Study Group, ASTRUM‐005 Study Group},
title = {First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial},
journal = {Cancer Communications},
year = {2025},
volume = {45},
number = {8},
pages = {990--1009},
doi = {10.1002/cac2.70032}
}
EUVIMED